发明名称 |
MicromiRs |
摘要 |
The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions. |
申请公布号 |
US8906871(B2) |
申请公布日期 |
2014.12.09 |
申请号 |
US200812681587 |
申请日期 |
2008.10.03 |
申请人 |
Santaris Pharma A/S |
发明人 |
Obad Susanna;Kauppinen Sakari;Elmén Joacim;Lindow Morten;Heidenblad Markus |
分类号 |
A61K48/00;C12N15/11;C07H21/02;C07H21/04 |
主分类号 |
A61K48/00 |
代理机构 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
代理人 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
主权项 |
1. An oligomer of a contiguous sequence of 7, 8, or 9 nucleotide units in length, for use in reducing the effective amount of a microRNA target in a cell or an organism, wherein at least 70% of the nucleotide units of the oligomer are selected from the group consisting of LNA (Locked Nucleic Acid) units and 2′ substituted nucleotide analogues, and wherein at least 50% of the nucleotide units of the oligomer are LNA units, and wherein at least one of the internucleoside linkages present between the nucleotide units of the contiguous nucleotide sequence is a phosphorothioate internucleoside linkage, wherein the contiguous nucleotide sequence is 100% complementary to the seed sequence of miR-21 (SEQ ID NO: 410), and wherein the seed sequence of miR-21 consists of nucleotides 2 to 8 of SEQ ID NO: 410 counting from the sequence's 5′ end. |
地址 |
Hørsholm DK |